Neurosterix

Switzerland
Hasle, Lucerne, Switzerland, 1202

Company profile

Neurosterix company profile

Neurosterix aims to create novel medicines based on allosteric modulation that overcome the limitations of traditional treatments and have the potential to significantly enhance patients' lives.

Business identity

Contact email
[email protected]
Operating status
Active
Company type
For Profit
Employee range
11-50 employees
Founded
2024-01-01, Year

Headquarters

Postal code
1202
Country code
CH
Continent
Europe

Capital profile

Funding and company signals

Funding stage
Early Stage Venture
Funding rounds
1
Total equity funding
$65M
Last funding
Series A / $65M / 2024-04-03
Last equity funding
Series A / $65M
Investors
4
Lead investors
1
Founders
1
Articles
19

Founders and investors

Founders

Tim Dyer

Lead investors

Perceptive Advisors

Investors

Acorn BioventuresAddex TherapeuticsPerceptive AdvisorsXontogeny